MannKind (NASDAQ:MNKD – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.
MNKD has been the topic of a number of other reports. Leerink Partnrs raised shares of MannKind to a “strong-buy” rating in a research report on Monday, September 9th. Leerink Partners initiated coverage on MannKind in a research report on Monday, September 9th. They set an “outperform” rating and a $8.00 price objective for the company. Finally, Oppenheimer upped their price target on MannKind from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.67.
View Our Latest Research Report on MannKind
MannKind Stock Down 1.9 %
Insider Transactions at MannKind
In related news, insider Stuart A. Tross sold 55,000 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $7.34, for a total value of $403,700.00. Following the completion of the sale, the insider now owns 967,191 shares in the company, valued at $7,099,181.94. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CEO Michael Castagna sold 85,106 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $6.30, for a total value of $536,167.80. Following the completion of the transaction, the chief executive officer now owns 2,294,836 shares in the company, valued at $14,457,466.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Stuart A. Tross sold 55,000 shares of the business’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $7.34, for a total transaction of $403,700.00. Following the completion of the sale, the insider now owns 967,191 shares in the company, valued at $7,099,181.94. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 250,161 shares of company stock valued at $1,632,795 in the last ninety days. 3.00% of the stock is currently owned by company insiders.
Institutional Trading of MannKind
Several institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC raised its position in shares of MannKind by 189.8% during the 2nd quarter. Millennium Management LLC now owns 4,744,519 shares of the biopharmaceutical company’s stock worth $24,766,000 after purchasing an additional 3,107,598 shares during the last quarter. TSP Capital Management Group LLC boosted its stake in shares of MannKind by 196.0% during the second quarter. TSP Capital Management Group LLC now owns 2,391,900 shares of the biopharmaceutical company’s stock valued at $12,486,000 after acquiring an additional 1,583,800 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in MannKind during the 2nd quarter worth about $1,524,000. Dark Forest Capital Management LP raised its stake in MannKind by 1,551.2% in the 2nd quarter. Dark Forest Capital Management LP now owns 275,970 shares of the biopharmaceutical company’s stock valued at $1,441,000 after purchasing an additional 259,257 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in MannKind by 15.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,885,370 shares of the biopharmaceutical company’s stock valued at $11,859,000 after purchasing an additional 251,587 shares in the last quarter. Hedge funds and other institutional investors own 49.55% of the company’s stock.
MannKind Company Profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.
See Also
- Five stocks we like better than MannKind
- Bank Stocks – Best Bank Stocks to Invest In
- Home Depot Stock: Targeting 12% in 2024 and 25% More in 2025
- Stock Market Upgrades: What Are They?
- Is Tesla’s Valuation a Bubble or Backed by Real Growth?
- 10 Best Airline Stocks to Buy
- Trucking Stocks Led the Pack Last Week: Can They Keep Rolling?
Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.